Oxycodone/Naloxone Stada Arzneimittel Ag (Naloxone, Oxycodone)

Naloxone, the active ingredient in Oxycodone/Naloxone Stada Arzneimittel Ag, is an opioid antagonist presented as a combination formulation for oral use. It is used in pain management to reduce opioid‑induced constipation while providing analgesia. GNH USA supplies Oxycodone/Naloxone Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodone/Naloxone Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/Naloxone is indicated for moderate to severe pain where opioid treatment is required and constipation is a concern.

- Chronic non‑cancer pain: provides effective analgesia while mitigating opioid‑induced bowel dysfunction. - Cancer‑related pain: delivers strong pain relief with reduced risk of constipation. - Post‑operative pain: manages acute pain after surgery and helps maintain bowel regularity. - Severe musculoskeletal pain: controls intense pain episodes while limiting gastrointestinal side effects. - Palliative care pain: offers comfort in end‑of‑life settings with lower constipation risk.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Nausea and vomiting - Constipation (when naloxone effect is insufficient) - Dizziness or light‑headedness - Dry mouth - Headache - Fatigue

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Acute withdrawal syndrome - Hepatotoxicity - Allergic reactions such as rash or angio‑edema - Cardiac arrhythmias

When prescribing Oxycodone/Naloxone, clinicians should consider patient‑specific factors and follow safe use guidelines.

- Assess pain severity: confirm that opioid therapy is appropriate. - Evaluate bowel function: monitor for signs of constipation or opioid‑induced bowel dysfunction. - Review concomitant CNS depressants: adjust dosing if sedatives or alcohol are used. - Check hepatic or renal impairment: dose may need adjustment. - Pregnancy and lactation: use only if benefits outweigh risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxycodone/Naloxone can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: heightened CNS depression and sedation. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase oxy‑dose exposure.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may alter oxycodone metabolism. - Anticholinergic agents: may worsen constipation if naloxone effect is insufficient. - Diuretics: can enhance hypotensive effects. - MAO inhibitors: may increase risk of serotonin syndrome. - Herbal supplements such as St St  St